Lupus Science & Medicine

Papers
(The H4-Index of Lupus Science & Medicine is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field51
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus51
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort50
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children46
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol42
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease39
Towards a minimal core dataset for systemic lupus erythematosus studies38
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus37
Genetic load in incomplete lupus erythematosus34
Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort30
Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality30
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms26
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases25
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE25
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus25
B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus24
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort24
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials23
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit22
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory22
Disease activity trajectories in paediatric lupus and associations with socioeconomic factors and patient-reported pain22
Mesenchymal stem cells improve ovarian function by suppressing fibrosis through CTGF/FAK signalling in systemic lupus erythematosus21
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response21
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial21
0.1057300567627